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Abstract
Background: It has been proposed that mesenchymal stromal cells (MSCs) promote tumor progression by interacting
with tumor cells and other stroma cells in the complex network of the tumor microenvironment. We characterized
MSCs isolated and expanded from tumor tissues of pediatric patients diagnosed with neuroblastomas (NB-MSCs) to
define interactions with the tumor microenvironment.
Methods: Specimens were obtained from 7 pediatric patients diagnosed with neuroblastoma (NB). Morphology,
immunophenotype, differentiation capacity, proliferative growth, expression of stemness and neural differentiation
markers were evaluated. Moreover, the ability of cells to modulate the immune response, i.e. inhibition of
phytohemagglutinin (PHA) activated peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cytotoxic
function, was examined. Gene expression profiles, known to be related to tumor cell stemness, Wnt pathway activation,
epithelial-mesenchymal transition (EMT) and tumor metastasis were also evaluated. Healthy donor bone
marrow-derived MSCs (BM-MSC) were employed as controls.
Results: NB-MSCs presented the typical MSC morphology and phenotype. They showed a proliferative capacity
superimposable to BM-MSCs. Stemness marker expression (Sox2, Nanog, Oct3/4) was comparable to BM-MSCs. NB-MSC
in vitro osteogenic and chondrogenic differentiation was similar to BM-MSCs, but NB-MSCs lacked adipogenic
differentiation capacity. NB-MSCs reached senescence phases at a median passage of P7 (range, P5-P13). NB-MSCs
exhibited greater immunosuppressive capacity on activated T lymphocytes at a 1:2 (MSC: PBMC) ratio compared with
BM-MSCs (p = 0.018). NK cytotoxic activity was not influenced by co-culture, either with BM-MSCs or NB-MSCs.
Flow-cytometry cell cycle analysis showed that NB-MSCs had an increased number of cells in the G0-G1 phase
compared to BM-MSCs. Transcriptomic profiling results indicated that NB-MSCs were enriched with EMT genes compared
to BM-MSCs.
Conclusions: We characterized the biological features, the immunomodulatory capacity and the gene expression profile
of NB-MSCs. The NB-MSC gene expression profile and their functional properties suggest a potential role in promoting
tumor escape, invasiveness and metastatic traits of NB cancer cells. A better understanding of the complex mechanisms
underlying the interactions between NB cells and NB-derived MSCs should shed new light on potential novel therapeutic
approaches.
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Background
Neuroblastoma (NB), one of the most common extracra-
nial solid tumors of childhood, arises from embryonic
neural crest cells. It may occur anywhere that sympa-
thetic neural tissue is found, but most frequently occurs
in the adrenal medulla. Other identifying characteristics
of this tumor include the early age of onset, high meta-
static disease frequency at diagnosis and the possibility
of spontaneous regression [1]. The most aggressive tu-
mors display amplification of the MYCN oncogene,
which is usually associated with poor survival, even in
localized disease.
Like most cancers, the effect of tumor microenviron-
ment on disease progression is not to be underestimate,
as highlighted by recent evidence [2–7]. This influence
is variable and it is determined by several factors, pro-
viding, in the early stages of tumor development, a phys-
ical barrier against tumorigenesis, with lymphocytes,
macrophages and natural killer (NK) cells playing key
roles in tumor suppression [8–10]. During cancer pro-
gression, tumor cells may create a supportive milieu that
promotes both tumor growth and metastasis by repro-
gramming the surrounding cells and molecules.
A role for mesenchymal stem cells (MSCs) in the pro-
motion of tumor progression by interacting with tumor
cells and other stroma cells in the complex network of the
microenvironment has been proposed [11]. It has been
demonstrated that NB cells upon pre-incubation with
MSCs developed a more invasive behavior towards the
bone marrow, primary site of NB metastases. Interestingly,
intratumorally injected BM-MSCs reduce NB tumor
growth and prolong murine survival, while after systemic
administration these cells fail to home and to reach the
primary tumor sites [12]; this observation suggests the
need for contact between MSCs and NB cells. Moreover,
MSCs have been shown to induce invasiveness of NB cells
via stimulation of CXCR4 expression both by secretome
production and enhanced SDF1/CXCR4 signaling. A cru-
cial role of the CXCL12/CXCR4 axis in promoting the NB
invasiveness and the cross-talk of NB cells with the micro-
environment has been assessed [13, 14].
The multiple properties of these cells such as self-
renewal, differentiation plasticity and ability to modulate
immune responses as well as their strong tropism for tu-
mors make them crucial players in the development of a
metastatic phenotype.
Little information is available regarding the biological
and functional features of MSCs isolated from NB tissue
(NB-MSCs) [15]. Therefore, the purpose of this study
was to characterize NB-MSCs in terms of morphology,
phenotype, differentiation, immunological capacity, pro-
liferative growth and gene expression profile to define
their involvement in the tumor microenvironment and
in NB progression.
Methods
Patients
Seven pediatric patients (3 females and 4 males; median
age 27 months, range 18–34 months), diagnosed with
NB were enrolled. The NB diagnosis was histologically
confirmed. In Table 1, clinical data, Ki67 positive cell
percentage and TP53 mutational status are reported.
Residual material for histological analysis was used as
the starting material for MSC isolation and expansion.
Samples were collected prior to chemotherapy. How-
ever, in one patient, samples were obtained pre- and
post-chemotherapy and in another patient only after
chemotherapy treatment.
The study was performed according to the Declaration
of Helsinki and with the approval of the Review Board
of the Children’s Hospital “G. Di Cristina” (register num-
ber 87 Civico 2017). Informed written consent was ob-
tained from the parents and/or legal guardian after
receiving information about the study.
Methods
Immunohistochemistry analysis on NB-tissue
In order to characterize the TP53 mutational status and
Ki67 proliferation index, which are associated with NB
prognosis, we performed an immunohistochemistry ana-
lysis on the seven NB patients enrolled in the study. Tis-
sue samples were fixed in 10% neutral buffered formalin
Table 1 Clinical data, neuroblastoma grading and prognostic index of the patients enrolled in the study
Patient Chemotherapy condition Tumor localization MYCN amplification Tumor stage INPCa MKIb Ki67 positive cells TP53
1 Pre abdominal yes IV unf > 4 < 10% mutated
2 Pre abdominal yes I unf ≤2 > 10% mutated
3 Pre abdominal yes IV unf > 4 > 10% wild type
4 Pre adrenal yes III unf < 2 > 10% wild type
5 Post abdominal yes IV unf > 4 > 10% mutated
6 Pre adrenal no III unf < 2 > 10% wild type
Post yes < 10% wild type
7 Pre abdominal yes IV unf > 2 > 10% mutated
aINPC International Neuroblastoma Pathology Classification, bMKI Mitosis-Karyorrhexis Index, unf Unfavorable
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for at least 24 h, washed in water for 30 min and placed
in ethanol 70% before the automated processing (Leica
ASP300 S system). Then, samples were included in High
Melt Paraffin (Surgipath Paraplast) and 5 μm thick sec-
tions were obtained by using the microtome. For immu-
nohistochemistry analysis of Ki67 and TP53 DO-7
staining, the slides were dewaxed and then subjected to
automated retrieval using DAKO PT link (Agilent) in
0.1M citrate buffer pH 6.0 or pH 9.0 according to the
manufacturer’s instructions. Upon overnight exposure at
4 °C to the following primary antibodies, Ki67 (mouse
IgG1; Dako Cytomation) and TP53 DO-7 (mouse IgG2b;
Novocastra Leica) tissue samples were incubated with
biotinylated anti-mouse by using the LSAB 2 Kit (Dako
Cytomation or Vectastain kit; Vector) following the
manufacturer’s instructions. Staining was detected using
3-amino-9- ethylcarbazole (AEC) chromogen. Nuclei
were counter-stained with hematoxylin (Sigma).
NB-MSC isolation, culture and expansion
MSCs were isolated after tumor tissue mechanical dissoci-
ation and collagenase type II treatment as previously de-
scribed [16]. The cell suspension was then collected and
cultured following standard expansion procedure for
bone-marrow MSC (BM-MSCs). Briefly, cells were plated
in polystyrene culture flasks (Corning Costar, Corning,
NY, USA) at a density of 160,000/cm2 in D-MEM+Gluta-
MAX (Gibco) supplemented with 10% FBS (Euroclone),
50mg/mL gentamicin and 1% penicillin.
NB-MSCs were isolated based on their ability to ad-
here to plastic as fibroblast-like cells, after being in cul-
ture at 37 °C in a humidified atmosphere with 5% CO2
and culture medium replacement twice a week. At ≥80%
confluence, NB-MSCs were harvested by Trypsin EDTA
(Euroclone), replated for expansion at a density of 4000
cells/cm2. Previously expanded and characterized BM-
MSCs were used as controls for the experiments de-
scribed in this study.
Characterization of ex-vivo expanded NB-MSCs
Proliferative capacity
Proliferative capacity was defined as cumulative Popula-
tion Doubling (cPD) calculated with the formula PD =
log10 (n. of harvested cells/n. of seeded cells)/log102.
Flow cytometry and cell cycle analysis
CD73, CD34, CD90, CD14, CD45, CD31, CD105, class
I-HLA and HLA-DR, (Beckman Coulter, IL, Milan, Italy)
were used for standard MSC characterization, as previ-
ously described [17]. Analysis of cell populations was
performed with a FACS Navios flow-cytometer (BC).
For stemness marker expression, cells were collected,
washed with PBS, fixed and permeabilized where neces-
sary using a Fix and Perm solution (BD Biosciences) for
20 min at room temperature. After washing, samples
were stained with primary antibodies against SOX2-
AlexaFluor488 (245,610, mouse IgG2a, BD), Nanog-Alexa
Fluor488 (N31–355, mouse IgG1k, BD), Oct-3/4-PE (40/
OCT3, mouse IgG1k, BD), CD117-PE (104D2, mouse,
IgG1k, BD), O4-PE (O4, mouse, IgGM, R&D systems),
and corresponding isotype matched controls against CD3
Alexa Fluor 488 (UCTHT1, IgG1k, BD Biosciences),
CD4-PE (L200, IgG1k, BD Biosciences) IgM-PE (Goat
Anti-Mouse, R&D systems), IgG2A-APC (Mouse, R&D
systems). Data were analyzed using AccuriC6 (BD).
Cell cycle analysis was performed on NB-MSCs and
BM-MSCs, using 50 μg/ml propidium iodide (Sigma-Al-
drich) in 0.1% sodium citrate (Sigma-Aldrich), 0.1% Tri-
ton X-100, 10 μg/ml RNAse (Sigma-Aldrich) containing-
buffer, after overnight incubation at 4 °C and measured
by flow cytometry. Data were analyzed with FlowJo soft-
ware (Tree Star).
Differentiation assays
The ability of NB-MSCs to differentiate into osteoblasts
and adipocytes was evaluated, as previously described
[18, 19]. For osteogenic differentiation, NB-MSCs were
cultured in induction medium, consisting of αMEM,
10% FBS, 10− 7 M dexamethasone, 50 mg/ml L-ascorbic
acid and 5mM β-glycerol phosphate (all from Sigma-
Aldrich). While adipogenic induction medium consisted
of αMEM, 10% FBS, 10-7M dexamethasone, 50 mg/ml
L-ascorbic acid and 5mM β-glycerol phosphate, 100 mg/
ml insulin, 50 mM isobutyl methylxanthine (all from
Sigma-Aldrich), 0.5 mM indomethacin (MP Biomedica,
Illkirch, France). Medium was changed twice a week and
differentiation was evaluated after 21 days. Osteogenic
differentiation was evaluated by staining for alkaline
phosphatase (AP) activity with Fast Blue and for calcium
deposition, with Alizarin Red S staining (both from
Sigma-Aldrich). While adipogenic differentiation was
demonstrated by the morphological appearance of fat
droplets stained with Oil Red O (Bio Optica, Milan,
Italy). The ability of NB-MSCs to differentiate in chon-
drocytes has been evaluated on adherent cells using the
hMSC Chondrogenic Differentiation Basal Medium
(Lonza), supplemented with TGFβ1 (10 ng/ml), IGF1
(100 ng/ml), transferrin (6.25 μg/ml), insulin (6.25 μg/
ml), TGFβ3 (5 ng/ml), 10% FBS and antibiotics (gentami-
cin and amphotericin) following manufacturing protocol.
Briefly, fresh medium was added every 3–4 days. After
21 days, cells were fixed with 2% PFA for 30min at 37 °
C, washed in PBS and stained with Alcian blue for 30
min, than evaluated with phase contrast microscopy.
Senescence assay
NB-MSC senescence was assessed by staining with the
β-galactosidase (SA-β-gal) staining kit (Cell Signaling
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Technology, Danvers, MA), according to the manufac-
turer’s instructions, and evaluated by direct-light
microscopy.
Immunomodulatory capacity
The ability of NB-MSC to modulate T lymphocytes pro-
liferation was evaluated as previously described [16].
Phytohemagglutinin (4 μg/ml, PHA-P; Sigma-Aldrich)
activated PBMCs were cultured in the presence or ab-
sence of MSCs at different NB-MSC: PBMC ratios (1:2,
1:20, and 1:200). After 48 h incubation at 37 °C, 5% CO2,
cultures were pulsed with 3H-thymidine (1 μCi/well, spe-
cific activity 6.7 μCi/mmole, Perkin Elmer, Waltham,
MA) and harvested after 18 h. 3H-thymidine incorpor-
ation was measured by gamma-counter (PerkinElmer
Massachusetts, USA). Experiments were performed in
triplicate and results were expressed as Stimulation
index (SI = cpm stimulated/cpm unstimulated).
NK mediated cytotoxic activity
NK activity was evaluated in effectors recovered from
PBMC/MSC mixed cultures in the presence (mixed cul-
ture) or absence (ctrl-culture) of MSCs. Briefly, 1 × 106
PBMCs obtained from one healthy donor were cultured
in RPMI 1640 (Euroclone, Milan, Italy), 5% autologous
plasma and 100 U/ml recombinant IL-2 (Novartis, Va-
rese, Italy) in the presence or absence of NB-MSC or
BM-MSC at a 1:10 MSC:PBMC ratio, in 24-well plates
for 24 h at 37 °C, 5% CO2. Recovered effectors (E) were
tested for their capacity to lyse 51Cr labelled K562 cells
(T) at 100:1, 30:1, 10:1 E:T ratios. After 4 h incubation,
25 μl of the supernatant was collected from each well
and counted for 1min in a gamma-counter (Topcount,
Packard, Downers Grove, Illinois). Results were expressed
as the percentage of T lysis calculated with the formula:
[(experimental release – spontaneous T release)/(total T
release – spontaneous T release)] × 100 [20].
RNA isolation and real-time PCR
Total RNA was extracted from cell pellets using an
RNeasy Mini Kit (Qiagen Inc., Hilden, Germany) and
quantitative reverse transcription-PCR (qRT-PCR) was
conducted as previously described [21]. In both BM-MSCs
and NB-MSCs, the expression of genes related to Stem-
ness, Wnt targets, EMT and Tumor Metastasis was
evaluated with the PrimePCR Assay according to the
manufacturer’s instructions (PrimePCR Custom Plate,
384-well, Biorad). Collected data were analyzed with the
PrimePCR Analysis software (Biorad).
Statistical analysis
Quantitative data were described as the mean and stand-
ard deviation. Statistical significance was determined by
analysis of variance (one-way or two ways) with the
Bonferroni post-test or the unpaired T-test. Signifi-
cance was defined as p ≤ 0.05. Analyses were per-
formed using the SPSS statistical package (SPSS,
Chicago) and Stata 8.0.
Results
NB-MSC isolation, expansion and differentiation
NB-MSCs were isolated and expanded from all NB tis-
sue. NB-MSCs were plastic adherent, displayed the typ-
ical spindle shape morphology and a proliferative
capacity (Fig. 1a, b). All NB-MSCs reached senescence
at an earlier phase compared to healthy donor
BM-MSCs (p = 0.03) [median passage P7 (range P5-P13)
and P15 (range P13-P21), respectively] (Fig. 1c).
NB-MSC in vitro differentiation towards different line-
ages, revealed an osteogenic and chondrogenic differen-
tiation potential similar to BM-MSCs and the lack of an
evident adipogenic differentiation capacity (Fig. 1d).
Phenotypical analysis of NB-MSCs
NB-MSCs in vitro expanded showed typical expression
of cell surface markers; they were positive for CD73,
CD90, CD105 and HLA-I and negative for CD34, CD45,
CD14, CD31 and HLA-DR (Fig. 2a and Additional file 1:
Figure S1). Similar to BM-MSCs, NB-MSCs showed
marked expression of stemness markers (Sox2, Nanog,
Oct3/4), neuroblastoma stemness marker (CD117), and
the oligodendrocyte marker O4 (Fig. 2b and Add-
itional file 2: Figure S2).
Cell cycle analysis of NB-MSCs
NB-MSC cell cycle analysis showed 91% of cells in the
G0-G1 phase, 2 and 5% in S and G2/M phase, respect-
ively, while in BM-MSC, 80% of cells were detected in
the G0-G1 phase, 7 and 10% in the S-phase and G2/M
phase, respectively (p = 0.03) (Fig. 3a and Additional file 3:
Figure S3).
Effect of NB-MSCs on PHA-induced PBMC proliferation
and NK activity
Regarding in vitro immunomodulatory capacity on acti-
vated T lymphocytes, NB-MSCs resulted more suppres-
sive at a ratio of 1:2 (MSC:PBMC) compared to
BM-MSCs (p = 0.018) (Fig. 3b). While NK cytotoxic ac-
tivity, evaluated after co-culture of whole PBMCs with
MSCs, was not influenced by co-culture either with
BM-MSCs or NB-MSCs.
Gene expression profiling of NB-MSCs
Gene expression profiling of Epithelial-to-Mesenchymal
Transition (EMT)-, stemness- and Wnt pathway- related
genes indicated that approximately 70% of these genes
were differently expressed in NB-MSCs compared to
BM-MSCs. In detail, 53 genes resulted up-regulated and
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27 genes down-regulated as showed in Tables 2 and 3,
respectively. In particular, Cadherin-2 (CDH2) and
Matrix metallopeptidase 9 (MMP9) were among the
most significantly up-regulated genes in NB-MSC com-
pared with BM-MSC (Fig. 4). These results suggest an
enhanced activation of the EMT program and increased
migratory capabilities in NB-MSCs that may facilitate
their potential role in promoting the invasiveness and
metastatic traits of NB cancer cells.
Discussion
In spite of the different medical interventions available,
the NB prognosis remains poor, accounting for over 15%
of all pediatric cancer deaths. At diagnosis, about 50% of
NB patients have metastases and even a higher percent-
age suffer from difficult to treat tumors [22–25]. Among
these patients only 40% survive long term despite treat-
ment with different therapeutic approaches [26–28]. The
interaction of neuroblastoma cancer-initiating cells with
their microenvironment has been reported to play an in-
tegral role in the maintenance of resistant disease and
tumor relapse [2].
The TME primarily consists of MSCs [15]. They are
multipotent cells, that can differentiate into several mes-
enchymal lineages, such as bone, adipose tissue, cartilage,
tendon and muscle [29–31]. Additionally, MSCs exert pe-
culiar immunomodulatory effects on several cells involved
in the immune response, both in vivo and in vitro,
through mechanisms that are not yet completely eluci-
dated [4, 6, 7]. MSCs have been experimentally shown to
be influenced by the tumor and subsequently regulate
tumor functions. In fact extracellular matrix components
have been shown to be influenced by tumor modified
MSCs thereby promoting tumor proliferation and metas-
tases [3–7]. As reported by Nakata et al., the exposure of
the MSCs to different types of tumor-derived exosomes,
including NB, induce the production of pro-tumorigenic
cytokines and chemokines, having a direct effect on tumor
Fig. 1 Characterization of ex-vivo expanded NB-MSCs. a morphology of culture-expanded MSCs obtained from representative NB-MSC and BM-MSC
cultures. MSCs from both the patient and donor display the characteristic spindle-shaped morphology. Original magnification × 4. b Cumulative PDs
from P1 to P5 of MSCs isolated from BM (black line) and from NB tumor tissue (grey line). The data represent the mean (±SD) of seven NB-MSC and
eight BM-MSC cultures. c Mean passages (±SD) at which BM-MSC (black bar) and NB-MSC (grey bar) entered senescence. d Osteogenic, adipogenic
and chondrogenic differentiation capacity of MSCs: the differentiation into osteoblasts is demonstrated by the histological detection of ALP activity (I)
and by the histological detection of calcium depositions positive for Alizarin Red S (II); the differentiation into adipocytes is revealed by the formation
of lipid droplets stained with oil red O (III); the differentiation into chondrocytes is shown by alcian blue staining (IV). Original magnification 20x
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cell proliferation and survival, on angiogenesis and on the
recruitment of other inflammatory cells that favour tumor
progression [32].
In the present study, NB-MSCs represent a population
that is similar, but not identical, to healthy donor
BM-MSCs. In detail, they exhibit different adipogenic
differentiation and immunomodulatory capabilities.
Moreover, NB-MSC gene expression profiling results
suggest their potential role in promoting the invasive-
ness and metastatic traits of NB cancer cells.
Under standard conditions, we isolated and propagated
MSCs derived from pediatric NB tissue at disease onset,
and in two cases after administration of chemotherapy.
MSCs isolated and propagated from pediatric NB tissue
displayed the typical MSC morphology and phenotype [33]
and proliferative capacity superimposable to BM-MSCs.
The similar expression levels of stemness markers, such as
Nanog, OCT3/4 and SOX2, observed both in NB-MSCs
and BM-MSCs, suggest that NB-MSCs, even when de-
rived from the tissue/tumor microenvironment, maintain
BM-MSC multipotentiality [30, 31].
In the cell cycle analysis, NB-MSCs showed an in-
creased number of cells in the G0-G1 phase compared
to BM-MSCs. It has been reported that a high content
Fig. 2 Phenotypical analysis of NB-MSC in comparison with BM-MSC. a MSCs are characterized by the expression of the typical surface markers:
CD73, CD90, HLA-I, CD105 and the absence of typical hematopoietic cell markers: CD34, CD31, CD14, CD45, and HLA-DR. NB-MSCs and BM-MSCs
showed identical phenotypical expression. b expression of stemness and differentiation markers Sox2, Nanog, Oct3/4, CD117, O4.Data in (a) and
(b) are expressed as the average percentage of positive cells (BM-MSC: black bar, NB-MSC: grey bar)
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of G1 phase-blocked cells in cancer might imply a still
unclear situation defined as “dormancy” that poses fun-
damental questions, which extend beyond the cancer
proliferation/suppressor balance in primary cancer [34].
In fact, dormant tumor cells are characterized by G0/G1
phase arrest and chemotherapeutic drugs resistance [34].
Our observation of NB-MSCs arrest in G0/G1 cell cycle
phase could support the essential role of MSCs, in regu-
lating cancer dormancy [35, 36]. These data provide a
valuable tool to understand the MSC role in tumorigen-
esis and therefore open new therapeutic avenues for the
prevention of cancer recurrence.
Regarding in vitro differentiation capabilities, NB-MSCs
revealed a similar osteogenic and chondrogenic differenti-
ation potential compared with BM-MSCs; on the contrary,
NB-MSCs did not differentiate into adipocytes. Even
though, tumor-MSCs exhibit varying differentiation cap-
abilities [37], according to our results, only a small subset
of MSCs isolated from pediatric neuroblastoma, teratoma,
Ewing sarcoma, and rhabdomyosarcoma specimens may
be induced to differentiate into adipocytes while they re-
spond to osteogenic induction similarly to BM-MSCs [34].
Nevertheless, the lack of evident adipocytic differentiation
together with an enhanced EMT-related gene expression
profile and a different immunological response, lead to the
hypothesis that NB-MSCs may be already dysregulated.
However, further studies are needed to determine whether
these cells could be defined as “cancer stem cells”.
The immunomodulatory properties of MSCs have
been demonstrated using different in vitro and in vivo
Fig. 3 Cell cycle analysis and immunomodulatory effect in 2 BM-MSC and 7 NB-MSC cultures. a Cell cycle analysis. The histogram shows the
relative cell number percentage in Sub-G0, G0/G1, S, G2/M phases. Data are expressed as the mean ± SD of 3 replicates. b In vitro effect of NB-
MSCs on PHA-induced PBMC proliferation
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study approaches. MSCs regulate immunity by interact-
ing with innate immune cells (including macrophages,
NK cells, and dendritic cells), and adaptive immune cells
(including B and T cells) [38–40]. In the present study,
we report more evident NB-MSC anti-proliferative ef-
fects on immune cells compared with BM-MSCs, con-
firming the impact of the tumor microenvironment on
MSC functions [7]. It is well known that NK cells are
potent anti-tumor cells [41] and possess strong cytotoxic
activity against NB, both in vitro [42] and in vivo [43].
Johann et al. [15] have reported that NK cytotoxicity is
significantly impaired after co-culture with tumor stro-
mal cells. Galland et al. [10] have demonstrated that
squamous cell lung carcinoma derived-MSCs exert a
more pronounced immunosuppressive effect on NK cell
functions and phenotype compared with the non tumor
derived-MSCs through different mechanisms. In our
study, the NK cytotoxic capability was not influenced by
co-culture either with BM-MSCs or with NB-MSCs. We
believe that these contrasting data may be ascribed to
the different culture conditions and the different starting
population, purified NK or whole PBMCs.
Abnormal regulation of TP53 has a critical role in
tumorigenesis. Velletri et al. [44] reported that MSC im-
munomodulatory properties may be influenced by the
TP53 mutational status, which leads to genome instability
Table 2 List of upregulated genes in NB-MSCs from NB patients compared with BM-MCs from healthy donors
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and subsequent functional alterations. About 50% of our
NB patients resulted TP53 mutated, in disagreement with
data reported in the literature, where 2% of patients are
mutated. Even if these results may depend on the small
number of patients, we believe that this mutational status
could affect the properties of NB-MSCs and tumor micro-
environment and dictate the conditions for cancer devel-
opment and progression [44]. Nevertheless, it is important
to consider that although TP53 is rarely mutated in NB, it
is functionally inactivated in the majority of both MYCN
amplified and MYCN WTsubsets NB [45–47].
It has been reported that tumor-derived MSCs may
promote cell invasiveness, migration and EMT of cancer
cells in many tumors [48, 49]. Recently, Rodriguez-Milla
et al. identified about 500 genes differentially expressed
in BM-MSCs from NB patients and BM-MSCs from
normal donors. Of note, genes involved in many bio-
logical processes including neurological system process,
apoptosis, cell adhesion, cell surface receptor and intra-
cellular signaling were up-regulated while genes related
to the immune response were down-regulated. These
findings suggest a dysregulation of crucial cellular path-
ways in MSCs in response to NB tumor [50].
Here, we found that the transcriptomic profiling of
NB-MSCs isolated from tumor samples derived from
NB patients was enriched in EMT-associated genes com-
pared to BM-MSCs, in particular in CDH2 and MMP-9
genes. It is known that CDH2, also termed N-cadherin,
favors transendothelial migration, and MMP-9, a key en-
zyme in extracellular matrix remodeling, promotes cell
invasion and metastasis by degrading collagens and fi-
bronectin. Moreover, high expression levels of CDH2 are
associated with a poor prognosis in NB and MMP-9 is
highly expressed in high-risk NB tumors [51–53]. Further-
more, in our gene expression profiling data NB-MSCs ex-
press higher levels of CXCR4 while down-regulate
Table 3 List of downregulated genes in NB-MCs from NB patients compared with BM-MCs from healthy donors
Fig. 4 Wnt signaling pathway, stemness and EMT program activation
are enhanced in NB-MSCs compared with BM-MSCs. Scatter plot of
the genes upregulated in NB-MSCs vs BM-MSCs (5 fold increase) are
reported in red, while the genes upregulated in BM-MSCs vs NB-MSCs
(5 fold increase) are marked in green. Data are presented as normalized
expression values of 3 biological replicates using the PrimePCR
Analysis software
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CXCL12 expression levels compared with BM-MSCs, sup-
porting the pivotal role of CXCL12/CXCR4 axis in pro-
moting NB invasiveness.
All together, these data provide evidence supporting a
role for NB-MSCs in facilitating the metastatic process
of NB cells, although further in vivo studies are needed
to demonstrate this hypothesis. We recognize that this
study has some limitations. The sample size was small,
but consistent with that of other studies investigating
this specific population. Additionally, the follow-up of
patients was too limited to be significant and provide
correlations. Despite these limitations, our findings sup-
port a role for NB-MSCs as a crucial factor on the mi-
croenvironmental regulation of tumor progression and
metastasis. Further studies analyzing a broader number
of samples are mandatory to confirm these results.
Conclusions
We describe a phenotypic and functional analysis of
NB-MSCs expanded from tumor tissue in comparison with
healthy BM-MSCs. NB- and BM-MSCs share important
similarities, however, there are some significant differences
in terms of functional properties and gene profile, that sug-
gest their potential role in promoting tumor escape, inva-
siveness and metastatic traits of NB cancer cells.
A better understanding of the complex mechanisms
underlying the interactions between NB cells and
NB-derived MSCs should shed light on potential novel
therapeutic approaches such as the use of MSCs as a
tool for drug-delivery.
Additional files
Additional file 1: Figure S1. Immunophenotype characterization of NB-
MSCs. Immunophenotype characterization of NB tissue derived-MSC from
a representative sample. NB-MSCs are gated on physical parameter (FSC
and SSC). Surface marker expression of NB-MSC are reported in overlay
histograms with light grey peaks representing negative control by isotype-
matched, nonreactive fluorochrome-conjugated antibodies. Dark grey peaks
represent positive cells. Histograms of surface marker expression are typical
of MSC being positive for CD105, CD73, CD90 and HLA-I and negative for
HLA-DR, CD31, CD14, CD45 and CD34. (JPG 132 kb)
Additional file 2: Figure S2. Flow cytometry profiles of selected stemness
markers in BM-MSCs and NB-MSCs. (Left panel) representative scatter plots of
SSC vs FSC of BM-MSC and NB-MSC cells. (Right panel) indicative flow
cytometry profiles of selected markers in BM-MSC and NB-MSC samples.
Dotted grey light histograms represent the relative isotype matched
control. (JPG 157 kb)
Additional file 3: Figure S3. Flow cytometry analysis in BM-MSCs and
NB-MSCs. Flow cytometry analysis of cell cycle in BM-MSCs and NB-MSCs.
Plots show the percentage of cells in sub-G0 phase (white box), G0-G1
phase (grey box), S phase (pink box) and G2-M phase (light yellow box).
(JPG 132 kb)
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